Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Revenue of Ipsen S.A. (IPN.PA)
Revenue in 2023 (TTM): $3.42 B
According to Ipsen S.A.'s latest financial reports the company's current revenue (TTM) is $3.42 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Ipsen S.A.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $3.42 B | $2.83 B | $1.18 B | $782.9 M | $667.24 M |
| 2022 | $3.27 B | $2.72 B | $1.17 B | $729.37 M | $671.59 M |
| 2021 | $2.85 B | $2.39 B | $1.1 B | $817.49 M | $669.52 M |
| 2020 | $2.78 B | $2.27 B | $822.56 M | $549.93 M | $567.43 M |
| 2019 | $2.79 B | $2.28 B | $158.11 M | $-36,033,633 | $-56,846,162 |
| 2018 | $2.43 B | $1.96 B | $667.86 M | $512.75 M | $403.31 M |
| 2017 | $2.08 B | $1.68 B | $504.16 M | $385.19 M | $281.95 M |
| 2016 | $1.73 B | $1.37 B | $400.72 M | $310.53 M | $233.91 M |
| 2015 | $1.57 B | $1.23 B | $364.06 M | $248.61 M | $196.63 M |
| 2014 | $1.38 B | $1.06 B | $293.24 M | $215.68 M | $158.94 M |
| 2013 | $1.33 B | $1.01 B | $260.73 M | $208.64 M | $157.95 M |
| 2012 | $1.32 B | $1.06 B | $205.21 M | $124.52 M | $-30,536,433 |
| 2011 | $1.28 B | $1.02 B | $153.24 M | $42.84 M | $439.03 K |
| 2010 | $1.21 B | $967.22 M | $172.26 M | $129.84 M | $99.07 M |
| 2009 | $1.15 B | $905.58 M | $224.32 M | $173.24 M | $162.74 M |
| 2008 | $1.07 B | $847.19 M | $255.53 M | $187.58 M | $152.9 M |
| 2007 | $1.03 B | $822.9 M | $257.88 M | $214.19 M | $156.42 M |
| 2006 | $892.22 M | $704.42 M | $246.19 M | $192.26 M | $149.11 M |
| 2005 | $816.67 M | $633.57 M | $197.16 M | $160.51 M | $123.46 M |
| 2004 | $749.65 M | $567.09 M | $156.01 M | $119.74 M | $85.94 M |